Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms?

Xiaoqin Huang, Xiaoyun Liu, Yongqiang Yu, Xiaoqin Huang, Xiaoyun Liu, Yongqiang Yu

Abstract

The occurrence of depression is higher in patients with chronic liver disease (CLD) than that in the general population. The mechanism described in previous studies mainly focused on inflammation and stress, which not only exists in CLD, but also emerges in common chronic diseases, leaving the specific mechanism unknown. This review was to summarize the prevalence and risk factors of depression in CLD including chronic hepatitis B, chronic hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease, and to point out the possible underlying mechanism of this potential link. Clarifying the origins of this common comorbidity (depression and CLD) may provide more information to understand both diseases.

Keywords: alcoholic liver disease (ALD); chronic liver disease (CLD); depression; hepatitis; non-alcoholic fatty liver disease (NAFLD).

References

    1. Adam R., Karam V., Delvart V., O’Grady J., Mirza D., Klempnauer J., et al. (2012). Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 57 675–688. 10.1016/j.jhep.2012.04.015
    1. Alcocer-Gómez E., de Miguel M., Casas-Barquero N., Nunez-Vasco J., Sanchez-Alcazar J. A., Fernandez-Rodriguez A., et al. (2014). NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav. Immun. 36 111–117. 10.1016/j.bbi.2013.10.017
    1. Altindag A., Cadirci D., Sirmatel F. (2009). Depression and health related quality of life in non-cirrhotic chronic hepatitis B patients and hepatitis B carriers. Neurosciences 14 56–59.
    1. Angulo P. (2002). Nonalcoholic fatty liver disease. N. Engl. J. Med. 346 1221–1231. 10.1056/NEJMra011775
    1. Arslan N., Buyukgebiz B., Ozturk Y., Akay A. P. (2003). Depression and anxiety in chronic hepatitis B: effect of hepatitis B virus infection on psychological state in childhood. Turk J. Pediatr. 45 26–28.
    1. Atesci F. C., Cetin B. C., Oguzhanoglu N. K., Karadag F., Turgut H. (2005). Psychiatric disorders and functioning in hepatitis B virus carriers. Psychosomatics 46 142–147. 10.1176/appi.psy.46.2.142
    1. Bellentani S., Tiribelli C., Saccoccio G., Sodde M., Fratti N., De Martin C., et al. (1994). Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos study. Hepatology 20 1442–1449. 10.1002/hep.1840200611
    1. Bianchi G., Marchesini G., Nicolino F., Graziani R., Sgarbi D., Loguercio C., et al. (2005). Psychological status and depression in patients with liver cirrhosis. Dig. Liver Dis. 37 593–600. 10.1016/j.dld.2005.01.020
    1. Bonaccorso S., Marino V., Biondi M., Grimaldi F., Ippoliti F., Maes M. (2002). Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J. Affect. Disord. 72 237–241. 10.1016/S0165-0327(02)00264-1
    1. Browning J. D., Szczepaniak L. S., Dobbins R., Nuremberg P., Horton J. D., Cohen J. C., et al. (2004). Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 1387–1395. 10.1002/hep.20466
    1. Bull S. J., Huezo-Diaz P., Binder E. B., Cubells J. F., Ranjith G., Maddock C., et al. (2009). Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 14 1095–1104. 10.1038/mp.2008.48
    1. Bulloch A., Lavorato D., Williams J., Patten S. (2012). Alcohol consumption and major depression in the general population: the critical importance of dependence. Depress. Anxiety 29 1058–1064. 10.1002/da.22001
    1. Burra P., Senzolo M., Adam R., Delvart V., Karam V., Germani G., et al. (2010). Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am. J. Transplant. 10 138–148. 10.1111/j.1600-6143.2009.02869.x
    1. Capuron L., Neurauter G., Musselman D. L., Lawson D. H., Nemeroff C. B., Fuchs D., et al. (2003). Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol. Psychiatry 54 906–914. 10.1016/S0006-3223(03)00173-2
    1. Capuron L., Schroecksnadel S., Feart C., Aubert A., Higueret D., Barberger-Gateau P., et al. (2011). Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol. Psychiatry 70 175–182. 10.1016/j.biopsych.2010.12.006
    1. Cargiulo T. (2007). Understanding the health impact of alcohol dependence. Am. J. Health Syst. Pharm. 64 S5–S11. 10.2146/ajhp060647
    1. Carta M. G., Hardoy M. C., Garofalo A., Pisano E., Nonnoi V., Intilla G., et al. (2007). Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin. Pract. Epidemiol. Ment. Health 3:22 10.1186/1745-0179-3-22
    1. Charlton M. R., Burns J. M., Pedersen R. A., Watt K. D., Heimbach J. K., Dierkhising R. A. (2011). Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141 1249–1253. 10.1053/j.gastro.2011.06.061
    1. Chitturi S., Farrell G. C., George J. (2004). Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J. Gastroenterol. Hepatol. 19 368–374. 10.1111/j.1440-1746.2003.03252.x
    1. Choi A. J., Ryter S. W. (2014). Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. Mol. Cells 37 441–448. 10.14348/molcells.2014.0104
    1. Clark J. M., Brancati F. L., Diehl A. M. (2002). Nonalcoholic fatty liver disease. Gastroenterology 122 1649–1657. 10.1053/gast.2002.33573
    1. Corruble E., Barry C., Varescon I., Falissard B., Castaing D., Samuel D. (2011). Depressive symptoms predict long-term mortality after liver transplantation. J. Psychosom. Res. 71 32–37. 10.1016/j.jpsychores.2010.12.008
    1. Cozzolongo R., Porcelli P., Cariola F., Giannuzzi V., Lanzilotta E., Gentile M., et al. (2015). Serotonin gene polymorphisms and lifetime mood disorders in predicting interferon-induced depression in chronic hepatitis C. J. Affect. Disord. 183 90–97. 10.1016/j.jad.2015.04.056
    1. Crum R. M., Storr C. L., Chan Y. F. (2005). Depression syndromes with risk of alcohol dependence in adulthood: a latent class analysis. Drug Alcohol Depend. 79 71–81. 10.1016/j.drugalcdep.2005.01.001
    1. Dan A. A., Martin L. M., Crone C., Ong J. P., Farmer D. W., Wise T., et al. (2006). Depression, anemia and health-related quality of life in chronic hepatitis C. J. Hepatol. 44 491–498. 10.1016/j.jhep.2005.11.046
    1. Dew M. A., Switzer G. E., DiMartini A. F. (1998). Psychiatric morbidity and organ transplantation. Curr. Opin. Psychiatry 11 621–626. 10.1097/00001504-199811000-00005
    1. DiMartini A., Dew M. A., Chaiffetz D., Fitzgerald M. G., Devera M. E., Fontes P. (2011). Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival. Am. J. Transplant. 11 1287–1295. 10.1111/j.1600-6143.2011.03496.x
    1. DiMatteo M. R., Lepper H. S., Croghan T. W. (2000). Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 160 2101–2107. 10.1001/archinte.160.14.2101
    1. Dwight M. M., Kowdley K. V., Russo J. E., Ciechanowski P. S., Larson A. M., Katon W. J. (2000). Depression, fatigue, and functional disability in patients with chronic hepatitis C. J. Psychosom. Res. 49 311–317. 10.1016/S0022-3999(00)00155-0
    1. el-Serag H. B., Kunik M., Richardson P., Rabeneck L. (2002). Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 123 476–482. 10.1053/gast.2002.34750
    1. Elwing J. E., Lustman P. J., Wang H. L., Clouse R. E. (2006). Depression, anxiety, and nonalcoholic steatohepatitis. Psychosom. Med. 68 563–569. 10.1097/01.psy.0000221276.17823.df
    1. Erim Y., Bottcher M., Dahmen U., Beck O., Broelsch C. E., Helander A. (2007). Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation. Liver Transpl. 13 757–761. 10.1002/lt.21163
    1. Ewusi-Mensah I., Saunders J. B., Wodak A. D., Murray R. M., Williams R. (1983). Psychiatric morbidity in patients with alcoholic liver disease. Br. Med. J. 287 1417–1419. 10.1136/bmj.287.6403.1417
    1. Fábregas B. C., Vieira É. L., Moura A. S., Carmo R. A., Ávila R. E., Abreu M. N., et al. (2016). A Follow-up study of 50 chronic hepatitis C patients: adiponectin as a resilience biomarker for major depression. Neuroimmunomodulation 23 88–97. 10.1159/000444531
    1. Fontana R. J., Schwartz S. M., Gebremariam A., Lok A. S., Moyer C. A. (2002). Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 43 378–385. 10.1176/appi.psy.43.5.378
    1. Forton D. M., Allsop J. M., Main J., Foster G. R., Thomas H. C., Taylor-Robinson S. D. (2001). Evidence for a cerebral effect of the hepatitis C virus. Lancet 358 38–39. 10.1016/S0140-6736(00)05270-3
    1. Galvao-de Almeida A., Quarantini L. C., Sampaio A. S., Lyra A. C., Parise C. L., Parana R., et al. (2011). Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C. Brain Behav. Immun. 25 1491–1497. 10.1016/j.bbi.2011.06.001
    1. Gilman S. E., Abraham H. D. (2001). A longitudinal study of the order of onset of alcohol dependence and major depression. Drug Alcohol. Depend. 63 277–286. 10.1016/S0376-8716(00)00216-7
    1. Gochee P. A., Powell E. E., Purdie D. M., Pandeya N., Kelemen L., Shorthouse C., et al. (2004). Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. Psychosomatics 45 49–57. 10.1176/appi.psy.45.1.49
    1. Gohier B., Goeb J. L., Rannou-Dubas K., Fouchard I., Cales P., Garre J. B. (2003). Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J. Biol. Psychiatry 4 115–118. 10.1080/15622970310029904
    1. Golden J., O’Dwyer A. M., Conroy R. M. (2005). Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen. Hosp. Psychiatry 27 431–438. 10.1016/j.genhosppsych.2005.06.006
    1. Grover V. P., Pavese N., Koh S. B., Wylezinska M., Saxby B. K., Gerhard A., et al. (2012). Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J. Viral. Hepat. 19 e89–e96. 10.1111/j.1365-2893.2011.01510.x
    1. Gutteling J. J., de Man R. A., van der Plas S. M., Schalm S. W., Busschbach J. J., Darlington A. S. (2006). Determinants of quality of life in chronic liver patients. Aliment. Pharmacol. Ther. 23 1629–1635. 10.1111/j.1365-2036.2006.02934.x
    1. Hauser P., Khosla J., Aurora H., Laurin J., Kling M. A., Hill J., et al. (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry 7 942–947. 10.1038/sj.mp.4001119
    1. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W. Z., Strowig T., et al. (2012). Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 179–185. 10.1038/nature10809
    1. Hensler J. G. (2003). Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci. 72 1665–1682. 10.1016/S0024-3205(02)02482-7
    1. Hojat M., Shapurian R., Mehryar A. H. (1986). Dimensionality of the short form of the beck depression inventory: a study with Iranian college students. Psychol. Rep. 59 1069–1070. 10.2466/pr0.1986.59.3.1069
    1. Horikawa N., Yamazaki T., Izumi N., Uchihara M. (2003). Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen. Hosp. Psychiatry 25 34–38. 10.1016/S0163-8343(02)00239-6
    1. Hui J. M., Kench J. G., Chitturi S., Sud A., Farrell G. C., Byth K., et al. (2003). Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38 420–427. 10.1053/jhep.2003.50320
    1. Irwin M., Daniels M., Bloom E. T., Smith T. L., Weiner H. (1987). Life events, depressive symptoms, and immune function. Am. J. Psychiatry 144 437–441. 10.1176/ajp.144.4.437
    1. Ismail K., Winkley K., Stahl D., Chalder T., Edmonds M. (2007). A cohort study of people with diabetes and their first foot ulcer: the role of depression on mortality. Diabetes Care 30 1473–1479. 10.2337/dc06-2313
    1. Karayiannis P., Thomas H. C. (2005). Is lamivudine a safe and effective therapy for patients with chronic hepatitis B and advanced liver disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 2 138–139. 10.1038/ncpgasthep0118
    1. Koff W. C., Fann A. V., Dunegan M. A., Lachman L. B. (1986). Catecholamine-induced suppression of interleukin-1 production. Lymphokine Res. 5 239–247.
    1. Kraus M. R., Al-Taie O., Schafer A., Pfersdorff M., Lesch K. P., Scheurlen M. (2007). Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 132 1279–1286. 10.1053/j.gastro.2007.02.053
    1. Kraus M. R., Schafer A., Csef H., Faller H., Mork H., Scheurlen M. (2001). Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig. Dis. Sci. 46 2060–2065. 10.1023/A:1011973823032
    1. Kunkel E. J., Kim J. S., Hann H. W., Oyesanmi O., Menefee L. A., Field H. L., et al. (2000). Depression in Korean immigrants with hepatitis B and related liver diseases. Psychosomatics 41 472–480. 10.1176/appi.psy.41.6.472
    1. Lavanchy D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral. Hepat. 11 97–107. 10.1046/j.1365-2893.2003.00487.x
    1. Lavanchy D. (2011). Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17 107–115. 10.1111/j.1469-0691.2010.03432.x
    1. Lee K., Otgonsuren M., Younoszai Z., Mir H. M., Younossi Z. M. (2013). Association of chronic liver disease with depression: a population-based study. Psychosomatics 54 52–59. 10.1016/j.psym.2012.09.005
    1. Leutscher P. D., Lagging M., Buhl M. R., Pedersen C., Norkrans G., Langeland N., et al. (2010). Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 52 430–435. 10.1002/hep.23699
    1. Li R., Wang X., Qin T., Qu R., Ma S. (2016). Apigenin ameliorates chronic mild stress-induced depressive behavior by inhibiting interleukin-1beta production and NLRP3 inflammasome activation in the rat brain. Behav. Brain Res. 296 318–325. 10.1016/j.bbr.2015.09.031
    1. Liu B., Xu C., Wu X., Liu F., Du Y., Sun J., et al. (2015). Icariin exerts an antidepressant effect in an unpredictable chronic mild stress model of depression in rats and is associated with the regulation of hippocampal neuroinflammation. Neuroscience 294 193–205. 10.1016/j.neuroscience.2015.02.053
    1. Lok A. S., van Leeuwen D. J., Thomas H. C., Sherlock S. (1985). Psychosocial impact of chronic infection with hepatitis B virus on British patients. Genitourin. Med. 61 279–282. 10.1136/sti.61.4.279
    1. Lopez-Figueroa A. L., Norton C. S., Lopez-Figueroa M. O., Armellini-Dodel D., Burke S., Akil H., et al. (2004). Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 55 225–233. 10.1016/j.biopsych.2003.09.017
    1. Lotrich F. E., Albusaysi S., Ferrell R. E. (2013). Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-alpha treatment. Neuropsychopharmacology 38 985–995. 10.1038/npp.2012.263
    1. Lotrich F. E., Ferrell R. E., Rabinovitz M., Pollock B. G. (2009). Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol. Psychiatry 65 344–348. 10.1016/j.biopsych.2008.08.009
    1. Lotrich F. E., Ferrell R. E., Rabinovitz M., Pollock B. G. (2010). Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin. Neuropharmacol. 33 191–197. 10.1097/WNF.0b013e3181de8966
    1. Lu M., Yang J. Z., Geng F., Ding J. H., Hu G. (2014). Iptakalim confers an antidepressant effect in a chronic mild stress model of depression through regulating neuro-inflammation and neurogenesis. Int. J. Neuropsychopharmacol. 17 1501–1510. 10.1017/S1461145714000285
    1. Lustman P. J., Anderson R. J., Freedland K. E., de Groot M., Carney R. M., Clouse R. E. (2000). Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23 934–942. 10.2337/diacare.23.7.934
    1. Lustman P. J., Clouse R. E., Ciechanowski P. S., Hirsch I. B., Freedland K. E. (2005). Depression-related hyperglycemia in type 1 diabetes: a mediational approach. Psychosom. Med. 67 195–199. 10.1097/
    1. Lustman P. J., Griffith L. S., Clouse R. E., Freedland K. E., Eisen S. A., Rubin E. H., et al. (1997). Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom. Med. 59 241–250. 10.1097/00006842-199705000-00007
    1. Lustman P. J., Griffith L. S., Freedland K. E., Kissel S. S., Clouse R. E. (1998). Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 129 613–621. 10.7326/0003-4819-129-8-199810150-00005
    1. Maddock C., Baita A., Orru M. G., Sitzia R., Costa A., Muntoni E., et al. (2004). Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J. Psychopharmacol. 18 41–46. 10.1177/0269881104040230
    1. Maes M., Song C., Lin A., De Jongh R., Van Gastel A., Kenis G., et al. (1998). The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 10 313–318. 10.1006/cyto.1997.0290
    1. Miller G. E., Freedland K. E., Carney R. M., Stetler C. A., Banks W. A. (2003). Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav. Immun. 17 276–285. 10.1016/S0889-1591(03)00057-6
    1. Mirabdolhagh Hazaveh M., Dormohammadi Toosi T., Nasiri Toosi M., Tavakoli A., Shahbazi F. (2015). Prevalence and severity of depression in chronic viral hepatitis in Iran. Gastroenterol. Rep. 3 234–237. 10.1093/gastro/gou091
    1. Mohd Hanafiah K., Groeger J., Flaxman A. D., Wiersma S. T. (2013). Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 1333–1342. 10.1002/hep.26141
    1. Muhlig Y., Antel J., Focker M., Hebebrand J. (2016). Are bidirectional associations of obesity and depression already apparent in childhood and adolescence as based on high-quality studies? A systematic review. Obes. Rev. 17 235–249. 10.1111/obr.12357
    1. Mullish B. H., Kabir M. S., Thursz M. R., Dhar A. (2014). Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment. Pharmacol. Ther. 40 880–892. 10.1111/apt.12925
    1. Naughton M., Mulrooney J. B., Leonard B. E. (2000). A review of the role of serotonin receptors in psychiatric disorders. Hum. Psychopharmacol. 15 397–415. 10.1002/1099-1077(200008)15:6<397::AID-HUP212<;2-L
    1. Navines R., Gomez E., Gasto C. (2003). [The 5-HT1A receptors: from molecular biology to neuropsychiatric symptoms]. Actas Esp. Psiquiatr. 31 272–283.
    1. Negash A. A., Ramos H. J., Crochet N., Lau D. T., Doehle B., Papic N., et al. (2013). IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 9:e1003330 10.1371/journal.ppat.1003330
    1. Neurauter G., Schrocksnadel K., Scholl-Burgi S., Sperner-Unterweger B., Schubert C., Ledochowski M., et al. (2008). Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr. Drug Metab. 9 622–627. 10.2174/138920008785821738
    1. Nouwen A., Winkley K., Twisk J., Lloyd C. E., Peyrot M., Ismail K., et al. (2010). Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 53 2480–2486. 10.1007/s00125-010-1874-x
    1. Okamura F., Tashiro A., Utumi A., Imai T., Suchi T., Tamura D., et al. (2000). Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 49 1255–1260. 10.1053/meta.2000.9515
    1. O’Shea R. S., Dasarathy S., McCullough A. J. (2010). Alcoholic liver disease. Hepatology 51 307–328. 10.1002/hep.23258
    1. Parkins M. D., McNeil S. A., Laupland K. B. (2009). Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention. Can. J. Infect. Dis. Med. Microbiol. 20 e81–e90. 10.1155/2009/474035
    1. Patten S. B., Williams J. V., Lavorato D. H., Modgill G., Jette N., Eliasziw M. (2008). Major depression as a risk factor for chronic disease incidence: longitudinal analyses in a general population cohort. Gen. Hosp. Psychiatry 30 407–413. 10.1016/j.genhosppsych.2008.05.001
    1. Penninx B. W., Kritchevsky S. B., Yaffe K., Newman A. B., Simonsick E. M., Rubin S., et al. (2003). Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol. Psychiatry 54 566–572. 10.1016/S0006-3223(02)01811-5
    1. Pierucci-Lagha A., Covault J., Bonkovsky H. L., Feinn R., Abreu C., Sterling R. K., et al. (2010). A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 51 137–148. 10.1176/appi.psy.51.2.137
    1. Popović D., Ćulafić D. M., Tepavčević D. B., Kovačević N. V., Špuran M. M., Djuranović S. P., et al. (2015). Assessment of depression and anxiety in patients with chronic liver disease. Vojnosanit. Pregl. 72 414–420. 10.2298/VSP130904007P
    1. Preiss K., Brennan L., Clarke D. (2013). A systematic review of variables associated with the relationship between obesity and depression. Obes. Rev. 14 906–918. 10.1111/obr.12052
    1. Raison C. L., Borisov A. S., Broadwell S. D., Capuron L., Woolwine B. J., Jacobson I. M., et al. (2005a). Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J. Clin. Psychiatry 66 41–48.
    1. Raison C. L., Borisov A. S., Woolwine B. J., Massung B., Vogt G., Miller A. H. (2010). Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol. Psychiatry 15 535–547. 10.1038/mp.2008.58
    1. Raison C. L., Demetrashvili M., Capuron L., Miller A. H. (2005b). Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19 105–123.
    1. Rice J. P., Eickhoff J., Agni R., Ghufran A., Brahmbhatt R., Lucey M. R. (2013). Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl. 19 1377–1386. 10.1002/lt.23762
    1. Rifai M. A., Sabouni M. A. (2012). Utilizing genomic polymorphisms to personalize hepatitis C therapies. Curr. Opin. Organ. Transplant. 17 198–203. 10.1097/MOT.0b013e328351093b
    1. Russ T. C., Kivimaki M., Morling J. R., Starr J. M., Stamatakis E., Batty G. D. (2015). Association between psychological distress and liver disease mortality: a meta-analysis of individual study participants. Gastroenterology 148 958–966.e4. 10.1053/j.gastro.2015.02.004
    1. Sakhuja P. (2014). Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis? World J. Gastroenterol. 20 16474–16479. 10.3748/wjg.v20.i44.16474
    1. Schaefer M., Capuron L., Friebe A., Diez-Quevedo C., Robaeys G., Neri S., et al. (2012). Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J. Hepatol. 57 1379–1390. 10.1016/j.jhep.2012.07.037
    1. Schaefer M., Engelbrecht M. A., Gut O., Fiebich B. L., Bauer J., Schmidt F., et al. (2002). Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 731–746.
    1. Schaefer M., Hinzpeter A., Mohmand A., Janssen G., Pich M., Schwaiger M., et al. (2007). Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 46 991–998. 10.1002/hep.21791
    1. Schaefer M., Schmidt F., Folwaczny C., Lorenz R., Martin G., Schindlbeck N., et al. (2003). Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37 443–451. 10.1053/jhep.2003.50031
    1. Schafer A., Scheurlen M., Felten M., Kraus M. R. (2005). Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatients. Eur. J. Gastroenterol. Hepatol. 17 1387–1394. 10.1097/00042737-200512000-00019
    1. Seitz H. K., Stickel F. (2007). Alcoholic liver disease in the elderly. Clin. Geriatr. Med. 23 905–921, viii 10.1016/j.cger.2007.06.010
    1. Singal A. K., Guturu P., Hmoud B., Kuo Y. F., Salameh H., Wiesner R. H. (2013). Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 95 755–760. 10.1097/TP.0b013e31827afb3a
    1. Singh N., Gayowski T., Wagener M. M., Marino I. R. (1997). Depression in patients with cirrhosis. Impact on outcome. Dig. Dis. Sci. 42 1421–1427. 10.1023/A:1018898106656
    1. Smith A. K., Simon J. S., Gustafson E. L., Noviello S., Cubells J. F., Epstein M. P., et al. (2012). Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-alpha-induced depression in patients with chronic hepatitis C. Mol. Psychiatry 17 781–789. 10.1038/mp.2011.67
    1. Stepanova M., Wai H., Saab S., Mishra A., Venkatesan C., Younossi Z. M. (2014). The portrait of an adult liver transplant recipient in the United States from 1987 to 2013. JAMA Intern. Med. 174 1407–1409. 10.1001/jamainternmed.2014.2903
    1. Su K. P., Huang S. Y., Peng C. Y., Lai H. C., Huang C. L., Chen Y. C., et al. (2010). Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol. Psychiatry 67 550–557. 10.1016/j.biopsych.2009.11.005
    1. Szabo G., Petrasek J. (2015). Inflammasome activation and function in liver disease. Nat. Rev. Gastroenterol. Hepatol. 12 387–400. 10.1038/nrgastro.2015.94
    1. Targher G., Bertolini L., Padovani R., Rodella S., Tessari R., Zenari L., et al. (2007). Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 1212–1218. 10.2337/dc06-2247
    1. Tomeno W., Kawashima K., Yoneda M., Saito S., Ogawa Y., Honda Y., et al. (2015). Non-alcoholic fatty liver disease comorbid with major depressive disorder: the pathological features and poor therapeutic efficacy. J. Gastroenterol. Hepatol. 30 1009–1014. 10.1111/jgh.12897
    1. Valentine A. D., Meyers C. A. (2005). Neurobehavioral effects of interferon therapy. Curr. Psychiatry Rep. 7 391–395. 10.1007/s11920-005-0042-3
    1. van Dooren F. E., Nefs G., Schram M. T., Verhey F. R., Denollet J., Pouwer F. (2013). Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS ONE 8:e57058 10.1371/journal.pone.0057058
    1. Wanless I. R., Lentz J. S. (1990). Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 1106–1110. 10.1002/hep.1840120505
    1. Weinstein A. A., Kallman Price J., Stepanova M., Poms L. W., Fang Y., Moon J., et al. (2011). Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics 52 127–132. 10.1016/j.psym.2010.12.019
    1. Weissenborn K., Ennen J. C., Bokemeyer M., Ahl B., Wurster U., Tillmann H., et al. (2006). Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 55 1624–1630. 10.1136/gut.2005.080267
    1. Wichers M. C., Kenis G., Koek G. H., Robaeys G., Nicolson N. A., Maes M. (2007). Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J. Psychosom. Res. 62 207–214. 10.1016/j.jpsychores.2006.09.007
    1. Widner B., Ledochowski M., Fuchs D. (2000). Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr. Drug Metab. 1 193–204. 10.2174/1389200003339063
    1. Wild S., Roglic G., Green A., Sicree R., King H. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 1047–1053. 10.2337/diacare.27.5.1047
    1. Wree A., Eguchi A., McGeough M. D., Pena C. A., Johnson C. D., Canbay A., et al. (2014a). NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 59 898–910. 10.1002/hep.26592
    1. Wree A., McGeough M. D., Pena C. A., Schlattjan M., Li H., Inzaugarat M. E., et al. (2014b). NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. 92 1069–1082. 10.1007/s00109-014-1170-1
    1. Xue J., Li H., Deng X., Ma Z., Fu Q., Ma S. (2015). L-Menthone confers antidepressant-like effects in an unpredictable chronic mild stress mouse model via NLRP3 inflammasome-mediated inflammatory cytokines and central neurotransmitters. Pharmacol. Biochem. Behav. 134 42–48. 10.1016/j.pbb.2015.04.014
    1. Youssef N. A., Abdelmalek M. F., Binks M., Guy C. D., Omenetti A., Smith A. D., et al. (2013). Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 33 1062–1070. 10.1111/liv.12165
    1. Youssef W., McCullough A. J. (2002). Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 13 17–30.
    1. Zhang Y., Liu L., Liu Y. Z., Shen X. L., Wu T. Y., Zhang T., et al. (2015). NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation. Int. J. Neuropsychopharmacol. 18:pyv006 10.1093/ijnp/pyv006
    1. Zhang Y., Liu L., Peng Y. L., Liu Y. Z., Wu T. Y., Shen X. L., et al. (2014). Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci. Ther. 20 119–124. 10.1111/cns.12170

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere